The Gamalei National Research Center for Epidemiology and Microbiology has developed a way to update the coronavirus vaccine, RIA Novosti reports with reference to the Institute CEO, Alexander Ginzburg.
“This is the same technology based on adenoviral vectors, where, according to the sequence of the spike protein, with a changed primary structure, a new sequence is synthesized literally during the day, and the next day it is inserted into the used vector, and practically you have a genetic engineering design that allows it to be used as a vaccine drug, ready,” said the scientist.
According to Ginzburg, the question is now being discussed whether in this case it is necessary to conduct all phases of the trials of the new vaccine. He recalled that in world practice there are examples when the drug was checked on a limited sample of up to a hundred people.
“If it gives the same adequate protective effect, but already against a new strain, it can be launched immediately into mass production. I hope that in the near future similar acts will be adopted with us, “said the scientist.
In August 2020, the Ministry of Health of Russia registered the world’s first vaccine for the prevention of COVID-19, developed by the Gamalei Research Center, which was called Sputnik V. Also registered in Russia are EpiVakKorona vaccines from the Vector Center of Rospotrebnadzor and KoviVak from the Chumakov Center of the Russian Academy of Sciences.